Valuation: Novo Nordisk A/S

Capitalization 1,144B 180B 153B 140B 133B 246B 16,782B 252B 1,647B 648B 8,097B 677B 663B 28,614B P/E ratio 2026 *
12.2x
P/E ratio 2027 * 12.3x
Enterprise value 1,255B 198B 168B 154B 146B 270B 18,404B 276B 1,806B 710B 8,880B 742B 727B 31,380B EV / Sales 2026 *
4.39x
EV / Sales 2027 * 4.18x
Free-Float
70.25%
Yield 2026 *
4.23%
Yield 2027 * 4.34%
1 day-0.96%
1 week+8.25%
Current month+11.69%
1 month+8.61%
3 months-33.79%
6 months-28.32%
Current year-20.71%
1 week 249.65
Extreme 249.65
264.5
1 month 226
Extreme 226
264.5
Current year 224.25
Extreme 224.25
409.95
1 year 224.25
Extreme 224.25
533.4
3 years 224.25
Extreme 224.25
1,033.2
5 years 224.25
Extreme 224.25
1,033.2
10 years 109.1
Extreme 109.1
1,033.2
Manager TitleAgeSince
Chief Executive Officer 56 2025-08-06
Director of Finance/CFO 55 2018-02-14
Chief Tech/Sci/R&D Officer 56 2025-08-06
Director TitleAgeSince
Director/Board Member 61 2017-03-22
Director/Board Member 51 2018-03-21
Director/Board Member 61 2022-03-23
Change 5d. change 1-year change 3-years change Capi.($)
-0.96%+8.25%-38.78%-53.88% 182B
-0.77%-1.04%+9.52%+145.43% 830B
-1.49%-3.06%+46.50%+41.03% 564B
-2.24%-1.34%+17.76%+25.95% 369B
+2.07%+0.88%+25.20%+15.27% 328B
-1.10%-0.24%+47.69%+24.50% 318B
-1.65%-2.54%+50.13%+2.57% 294B
-0.50%-1.99%+30.44%+34.11% 291B
-1.45%+0.10%+26.28%+43.83% 192B
-1.29%-2.27%+29.97%+60.43% 171B
Average -0.55%-0.18%+24.47%+33.92% 353.84B
Weighted average by Cap. -0.52%-0.65%+25.66%+52.49%

Financials

2026 *2027 *
Net sales 286B 45.09B 38.26B 35.07B 33.3B 61.55B 4,193B 62.86B 411B 162B 2,023B 169B 166B 7,150B 298B 47.06B 39.94B 36.61B 34.76B 64.25B 4,377B 65.62B 429B 169B 2,112B 177B 173B 7,463B
Net income 92.25B 14.55B 12.35B 11.32B 10.75B 19.86B 1,353B 20.28B 133B 52.21B 653B 54.57B 53.44B 2,307B 94.3B 14.87B 12.62B 11.57B 10.98B 20.3B 1,383B 20.73B 136B 53.37B 667B 55.78B 54.63B 2,358B
Net Debt 111B 17.44B 14.8B 13.57B 12.88B 23.81B 1,622B 24.32B 159B 62.6B 783B 65.43B 64.07B 2,766B 103B 16.28B 13.82B 12.66B 12.03B 22.22B 1,514B 22.7B 149B 58.43B 731B 61.07B 59.8B 2,582B
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).
Employees
69,150
Date Price Change Volume
26-04-20 257.90 kr -0.96% 4,026,953
26-04-17 260.40 kr +1.24% 6,440,769
26-04-16 257.20 kr +2.12% 7,032,523
26-04-15 251.85 kr +2.32% 6,242,006
26-04-14 246.15 kr +3.32% 6,509,512
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
257.90DKK
Average target price
307.67DKK
Spread / Average Target
+19.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NOVO B Stock